OBJECTIVE: To study the effects of addition of spironolactone to angiotensin-converting enzyme (ACE) inhibition or angiotensin II (AngII) receptor antagonism on proteinuria, blood pressure (BP) and renal function in overt type 2 diabetic nephropathy. DESIGN: A placebo-controlled, double-blind, parallel-group trial in patients from two outpatient clinics with a follow-up of 1 year. METHODS: Type 2 diabetic patients with macroalbuminuria, despite long-term use of an ACE inhibitor or AngII receptor blocker were allocated to spironolactone, 25-50 mg once daily (n = 29) or placebo (n = 30). Urinary albumin to creatinine ratio, BP and biochemical parameters were measured at regular intervals. RESULTS: Five patients of the spironolactone and one of the placebo group developed hyperkalemia and had to be excluded. Compared to other patients their baseline serum creatinine [161 (123-248) versus 88 (72-170) μmol/l] and potassium concentrations (4.7 ± 0.3 versus 4.2 ± 0.2 mmol/l) were elevated (P < 0.001). Albuminuria decreased by 40.6% [95% confidence interval (CI) 23.4-57.8%] and BP by 7 mmHg (2-12 mmHg)/3 mmHg (1-6 mmHg) with spironolactone, but did not change with placebo. Estimated glomerular filtration rate (eGFR) during the 1-year follow-up declined on average by 12.9 ml/min per 1.73 m (9.5-16.5 ml/min per 1.73 m) in the spironolactone and by 4.9 ml/min per 1.73 m (0.8-8.9 ml/min per 1.73 m) in the placebo group (P = 0.004). This decline was progressive in the placebo but leveled off in the spironolactone group. In the spironolactone group changes in albuminuria and GFR were correlated (r = 0.48, P = 0.007). CONCLUSION: Addition of spironolactone to an ACE inhibitor or AngII receptor blocker is associated with a marked and sustained antiproteinuric effect, which in part relates to the more pronounced reduction in GFR.

Additional Metadata
Keywords Diabetes mellitus, Nephropathy, Proteinuria, Spironolactone
Persistent URL dx.doi.org/10.1097/01.hjh.0000249708.44016.5c, hdl.handle.net/1765/68743
Journal Journal of Hypertension
Citation
van den Meiracker, A.H, Baggen, M.G.A, Pauli, S, Lindemans, A, Vulto, A.G, Poldermans, D, & Boomsma, F. (2006). Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. Journal of Hypertension, 24(11), 2285–2292. doi:10.1097/01.hjh.0000249708.44016.5c